Bedrijfsoverzicht
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology entity focused on the development and commercialization of T cell-based immunotherapies designed to treat hematological malignancies and solid tumor indications within the United States. The company operates within the Healthcare sector, specifically in the Biotechnology industry, which typically involves high capital expenditure and lengthy research and development cycles to bring new biological agents to market. As of the latest reporting period, the company maintains a market capitalization of $22.64M, reports annual revenue of $3.55M, and employs a workforce of 5 individuals. These financial figures indicate that Marker Therapeutics is a micro-cap biotechnology firm with minimal operational scale, reflecting the early-stage nature of its pipeline where revenue generation is often limited while significant resources are directed toward clinical trials and technology maturation.
Financiële gezondheid
Marker Therapeutics reported a revenue of $3.55M over the trailing twelve months, yet the company recorded a net income loss of $-12,163,620, highlighting a substantial disconnect between top-line sales and bottom-line profitability. The absence of reported EBITDA figures suggests that operating costs, particularly in R&D and clinical development, far exceed the revenue generated, a common characteristic for clinical-stage biotech firms before product approval. The company generated free cash flow of $-8,598,567, which indicates a reliance on external financing to fund operations and development activities rather than self-sufficiency from current cash flows. Profitability metrics are deeply negative, with a gross margin of -232.7%, an operating margin of -170.7%, and a profit margin of 0.0%, all pointing to an aggressive burn rate where costs significantly outweigh revenues. Despite the negative earnings, the company holds $16.07M in cash against zero debt, resulting in a debt-to-equity ratio listed as N/A due to the lack of debt obligations. This balance sheet structure is conservative regarding leverage but presents a liquidity risk if cash reserves are depleted before clinical milestones are achieved. The current ratio stands at 8.39, indicating that the company possesses ample short-term assets relative to its liabilities, providing a significant buffer against immediate financial obligations. Furthermore, the return on equity is -68.8% and the return on assets is -37.8%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than positive returns.
Waarderingsbeoordeling
The company presents a trailing P/E ratio that is N/A due to its negative net income, while the forward P/E is calculated at -9.21, implying that the market prices in future earnings recovery without accounting for the current period's losses. The price-to-book ratio is 1.74, suggesting that the market values the company at a premium of 74% above its net asset book value, which may reflect intangible value in its intellectual property and pipeline potential. Alternative valuation metrics such as the price-to-sales ratio of 6.38 and the EV/EBITDA of N/A provide context for investors, showing that the stock is priced significantly relative to its sales volume in a manner typical for pre-revenue biotechs. The stock has traded between a 52-week low of $0.81 and a 52-week high of $4.07, with the current trading price positioned within this volatile range. The beta of 1.47 indicates that the stock exhibits 47% higher volatility than the broader market, meaning price movements are amplified compared to large-cap indices. These valuation metrics collectively suggest a high-risk, high-reward profile where the market is pricing in significant potential upside contingent on clinical success, yet acknowledging the current lack of profitability.
Growth & Income
The company experienced a revenue growth rate of -51.0% year-over-year, while earnings growth is N/A due to the reported losses, indicating that the business is contracting in terms of sales rather than expanding. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically available for reinvestment, although in this instance, the company is burning cash to sustain operations. The inability to pay dividends is consistent with the company's life cycle stage, where capital is prioritized for research and development over shareholder distributions. Overall, Marker Therapeutics demonstrates a negative growth trajectory in revenue with no income generation, positioning it as a pure-play speculative asset dependent on future clinical outcomes rather than current operational performance.